Hangzhou Diagens Biotechnology Co., Ltd./ADR

Over the past 90 days, Hangzhou Diagens Biotechnology (HGZDY) has reported zero cyber incidents and zero red-flag 8-K filings including bankruptcy, delisting, restatement, or officer departures. This absence of near-term event risk provides a baseline snapshot, though low signal in a 90-day window does not preclude material risks embedded in earlier periods or structural vulnerabilities. The full $49 Report expands the analysis to a 12-month lookback, adds a dilution risk score derived from cap table trends, contextualizes any 8-K filings against financing history, and surfaces AI-related operational and regulatory risk signals. The full $49 Report adds quantified shareholder dilution risk, historical 8-K pattern analysis, and biotech-specific leverage and burn-rate metrics that shape longer-term viability.